Oncogenic Signaling Pathways in The Cancer Genome Atlas.

Fiche du document

Date

5 avril 2018

Type de document
Périmètre
Langue
Identifiants
Relations

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1016/j.cell.2018.03.035

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/29625050

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1097-4172

Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_03A6331C652C4

Licences

info:eu-repo/semantics/openAccess , Copying allowed only for non-profit organizations , https://serval.unil.ch/disclaimer




Citer ce document

F. Sanchez-Vega et al., « Oncogenic Signaling Pathways in The Cancer Genome Atlas. », Serveur académique Lausannois, ID : 10.1016/j.cell.2018.03.035


Métriques


Partage / Export

Résumé 0

Genetic alterations in signaling pathways that control cell-cycle progression, apoptosis, and cell growth are common hallmarks of cancer, but the extent, mechanisms, and co-occurrence of alterations in these pathways differ between individual tumors and tumor types. Using mutations, copy-number changes, mRNA expression, gene fusions and DNA methylation in 9,125 tumors profiled by The Cancer Genome Atlas (TCGA), we analyzed the mechanisms and patterns of somatic alterations in ten canonical pathways: cell cycle, Hippo, Myc, Notch, Nrf2, PI-3-Kinase/Akt, RTK-RAS, TGFβ signaling, p53 and β-catenin/Wnt. We charted the detailed landscape of pathway alterations in 33 cancer types, stratified into 64 subtypes, and identified patterns of co-occurrence and mutual exclusivity. Eighty-nine percent of tumors had at least one driver alteration in these pathways, and 57% percent of tumors had at least one alteration potentially targetable by currently available drugs. Thirty percent of tumors had multiple targetable alterations, indicating opportunities for combination therapy.

document thumbnail

Par les mêmes auteurs

Sur les mêmes sujets

Exporter en